Evid Based Med 18:e13 doi:10.1136/eb-2012-100836
  • Online articles
  • Systematic review with meta-analysis

Metformin may not reduce cardiovascular risk or all-cause mortality

  1. Matteo Monami
  1. Correspondence to: Matteo Monami
    Department of Cardiovascular Medicine, Section of Diabetes, Cardiovascular and Geriatric Medicine, University of Florence and Careggi Teaching Hospital, Via delle Oblate 4, Florence 50141, Italy; mmonami{at}

Commentary on:


The treatment of hyperglycaemia is considered as one of the tools for preventing cardiovascular disease in Type 1 and Type 2 diabetic (T2D) patients.1 ,2 Metformin is recommended as the first-line drug for T2D by most international guidelines (IDF.2005., 2007.,, The preference for metformin over other available drugs is based on its efficacy on blood glucose control, tolerability, safety and low cost (IDF.2005., 2007.,, Metformin seems to have a favourable profile of action on several extraglycaemic risk factors, including lipids, …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article